Profusa, Inc.

Stage 4 · Declining · week 25

As of Oct 22, 2026, Profusa is in Stage 4, the downtrend phase, now in week 25 (since Apr 27, 2026). It closed at $1.02, 100.0% below its 52-week high and below its 200-day average, which is falling.

$1.02

+20.14% today

$617,759 · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is PFSA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2025-07-11 → 2026-10-22

S? 41w

S4 26w

2025-07-112026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 41w → S4 26w current

Total tracked: 67 weeks across 2 stage runs.

PFSA among Medical Devices134th of 141 by relative strength

All 141 →

Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	TXG10x Genomics, Inc.	Stage 2 · wk 48	99	−7.8%
2	RCELAvita Medical, Inc.	Stage 2 · wk 13	98	+40.8%
3	BFLYButterfly Network, Inc. Class A	Stage 2 · wk 26	98	−26.0%
4	HAEHaemonetics Corporation	Stage 2 · wk 17	96	+8.7%
5	GKOSGlaukos Corporation	Stage 2 · wk 25	96	+15.1%
6	AXGNAxogen, Inc.	Stage 3 · wk 2	95	−15.3%
7	NEOGNeogen Corporation	Stage 2 · wk 14	95	−11.7%
8	BVSBioventus Inc. Class A	Stage 2 · wk 15	95	+10.5%
…134	PFSAProfusa, Inc.	Stage 4 · wk 25	1	−50.2%

vs 52W High

-100.0%

$0.85 lo$2,220.00 hi

100.0% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 25

1w13w26w

Week 25, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-99.1%

200 DMA: $115.53 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

12.63x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-50.2%

-85.1%

-98.3%

YTD

-99.9%

-100.0%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S4

Wk 25 · Vol 12.63x

2026-10-21S4

Wk 25 · Vol 0.06x

2026-10-20S4

Wk 25 · Vol 0.04x

2026-10-19S4

Wk 25 · Vol 0.03x

2026-10-16S4

Wk 25 · Vol 0.04x

2026-10-15S4

Wk 24 · Vol 1.00x

2026-10-14S4

Wk 24 · Vol 0.18x

2026-10-13S4

Wk 24 · Vol 0.03x

2026-10-12S4

Wk 24 · Vol 0.08x

2026-10-09S4

Wk 24 · Vol 0.07x

2026-10-08S4

Wk 23 · Vol 0.24x

2026-10-07S4

Wk 23 · Vol 0.12x

Moving averages & range

50 DMA

$3.19

200 DMA

$115.53

52W High

$2,220.00

52W Low

$0.85

5D Low

$0.85

Resistance levels (recent highs)

20d High

$2.27

60d High

$27.48

120d High

$55.70

250d High

$2,220.00

Next resistance

+122.5%

to 20d High

P/E (TTM)

0.0

Forward —

Dividend Yield

0.00%

P/B -0.0

Profusa: quick answers

What stage is Profusa in?

As of Oct 22, 2026, Profusa (PFSA) is in Stage 4, the downtrend phase. It entered Stage 4 on Apr 27, 2026 and is in week 25. What the four stages mean

Is Profusa in an uptrend?

No. Profusa is in a Stage 4 downtrend. It trades 99.1% below its 200-day average, which is falling.

How far is Profusa from its 52-week high?

Profusa closed at $1.02 on Oct 22, 2026, 100.0% below its 52-week high of $2,220.00. Its 52-week low is $0.85.

How has Profusa performed over the past year?

As of Oct 22, 2026, Profusa is down 100.0% over the past year and down 99.9% so far in 2026.

Which sector and industry is Profusa in?

Profusa is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.